Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient
Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes. GLASGOW, Scotland, June 13, 2023 /PRNewswire/ — Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th … Read more